Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 1/20 | 0.61 |
| ▸ | DRD3 | P35462 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.53 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.53 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29683253 | 1.00 | GLS (0.61) | GLSDRD3MEN1CYP1A2CHRM2 | |
| Bromide SCHEMBL17510030 | 0.98 | GLS (0.59) | GLSDRD3MEN1CYP1A2CHRM2 | |
| SCHEMBL27494119 | 0.90 | GLS (0.52) | GLSDRD3CASP3 | |
| SCHEMBL29511230 | 0.87 | CHRM2 (0.61) | MEN1CYP1A2CHRM2CYP2C19KMT2A | |
| SCHEMBL149620 | 0.87 | CHRM2 (0.61) | MEN1CYP1A2CHRM2CYP2C19KMT2A | |
| SCHEMBL5151493 | 0.86 | DRD3 (0.50) | GLSDRD3 | |
| SCHEMBL10335609 | 0.86 | DRD3 (0.50) | GLSDRD3 | |
| SCHEMBL6699936 | 0.85 | GLS (0.71) | GLSNPC1CASP3RAB9ASMN1; SMN2 | |
| SCHEMBL19297268 | 0.85 | ALDH1A1 (0.62) | DRD3CHRM2 | |
| SCHEMBL29418113 | 0.85 | ALDH1A1 (0.67) | MEN1CYP1A2CHRM2CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 382 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114349678-B | Continuous industrial production method of N-alkyl-nitrophthalimide | 珠海派锐尔新材料有限公司 | 2024-04-26 | — | — | CN | claimed |
| CN-114349678-A | Continuous industrial production method of N-alkyl-nitrophthalimide | 珠海派锐尔新材料有限公司 | 2022-04-15 | — | — | CN | claimed |
| CN-110306346-A | A kind of refining dye enzyme and preparation method thereof promoting the anti-fuzz balls performance of cotton knitwear | 广东湛丰精细化工有限公司 | 2019-10-08 | — | — | CN | claimed |
| US-20160311773-A1 | GLUCOSE METABOLISM MODULATING COMPOUNDS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2016-10-27 | — | — | US | claimed |
| CN-101490334-B | Substantially flame retardant-free 3GT carpet | DU PONT | 2012-09-05 | — | — | CN | claimed |
| US-20120135089-A1 | E3 LIGASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-05-31 | — | — | US | claimed |
| US-8148537-B2 | Substituted acetophenones useful as PDE4 inhibitors | LEO PHARMA A/S (DK) | 2012-04-03 | — | — | US | claimed |
| US-20110118300-A1 | GLUCOSE METABOLISM MODULATING COMPOUNDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-05-19 | — | — | US | claimed |
| EP-2125736-B1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | LEO PHARMA AS (DK) | 2011-03-30 | — | — | EP | claimed |
| WO-2010107485-A1 | E3 LIGASE INHIBITORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-09-23 | — | — | WO | claimed |
| US-20060069262-A1 | Oxadiazoles and their manufacture | EASTMAN KODAK COMPANY | 2006-03-30 | — | — | US | claimed |
| US-20030050310-A1 | Hydroxamic acid derivatives as proteinase inhibitors | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2003-03-13 | — | — | US | claimed |
| US-6479502-B1 | TREATMENT OF DISEASES AND CONDITIONS RESPONSIVE TO MODULATION OF MATRIX METALLOPROTEINASE ACTIVITY | BRITISH BIOTECH PHARMACEUTICALS (GB) | 2002-11-12 | — | — | US | claimed |
| EP-1107953-A1 | HYDROXAMIC ACID DERIVATIVES AS PROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2001-06-20 | — | — | EP | claimed |
| WO-2000012477-A1 | HYDROXAMIC ACID DERIVATIVES AS PROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-03-09 | — | — | WO | claimed |
| US-5719295-A | FROM N-ALKYL NITROPHTHALAMIDE | GENERAL ELECTRIC COMPANY (US) | 1998-02-17 | — | — | US | claimed |
| US-5688312-A | INKS WITH COLORS AND IMIDES OR BISIMIDES, FOR ACOUSTIC INK PRINTER AND DROP EJECTOR | XEROX CORPORATION (US) | 1997-11-18 | — | — | US | claimed |
| EP-0164409-B1 | METHOD FOR MAKING N-SUBSTITUTED NITROPHTHALIMIDES | GENERAL ELECTRIC COMPANY (US) | 1989-08-02 | — | — | EP | claimed |
| EP-0164409-A1 | METHOD FOR MAKING N-SUBSTITUTED NITROPHTHALIMIDES. | GEN ELECTRIC (US) | 1985-12-18 | — | — | EP | claimed |
| WO-1985002612-A1 | METHOD FOR MAKING N-SUBSTITUTED NITROPHTHALIMIDES | GENERAL ELECTRIC COMPANY (US) | 1985-06-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118300-A1 | GLUCOSE METABOLISM MODULATING COMPOUNDS | SLC2A4, SLC2A2, SLC2A1 | GLS 49/4885DRD3 604/4885MEN1 2600/4885 |
| US-20120135089-A1 | E3 LIGASE INHIBITORS | MDM2, RBX1, XIAP | GLS 2863/4885DRD3 4572/4885MEN1 2333/4885 |
| US-20030050310-A1 | Hydroxamic acid derivatives as proteinase inhibitors | MMP2, CTSH, TIMP3 | GLS 542/4885DRD3 4718/4885MEN1 3457/4885 |
| US-20060069262-A1 | Oxadiazoles and their manufacture | OXA1L, CYP1B1, OXER1 | GLS 2705/4885DRD3 478/4885MEN1 1167/4885 |
| US-20160311773-A1 | GLUCOSE METABOLISM MODULATING COMPOUNDS | SLC2A4, SLC2A2, SLC2A1 | GLS 36/4885DRD3 597/4885MEN1 2768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.